Oncimmune Holdings Management

Management criteria checks 3/4

Oncimmune Holdings' CEO is Martin Gouldstone, appointed in Aug 2023, has a tenure of 1.25 years. directly owns 0.092% of the company’s shares, worth €18.89K. The average tenure of the management team and the board of directors is 4.8 years and 5.6 years respectively.

Key information

Martin Gouldstone

Chief executive officer

UK£21.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	1.3yrs
CEO ownership	0.09%
Management average tenure	4.8yrs
Board average tenure	5.6yrs

Recent management updates

Recent updates

CEO

Martin Gouldstone (58 yo)

1.3yrs

Tenure

UK£21,000

Compensation

Mr. Martin John Gouldstone is Chief Executive Officer and Director of Oncimmune Holdings plc from August 1, 2023. He serves as an Independent Non-Executive Director of ValiRx Plc since April 22, 2024 and s...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Martin Gouldstone	CEO & Director	1.3yrs	UK£21.00k	0.092% € 18.9k
Ron Kirschner	COO, General Counsel & Company Secretary	4.6yrs	UK£27.00k	no data
Martin Hudson	Finance Director	1.2yrs	no data	no data
Tariq Sethi	Chief Scientific Officer	5.1yrs	no data	no data
Cléa Rosenfeld	Head of Investor Relations	5.3yrs	no data	no data
Maarten Brusse	Chief Commercial Officer of Asia	8.2yrs	no data	no data

4.8yrs

Average Tenure

Experienced Management: OCY's management team is considered experienced (4.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Martin Gouldstone	CEO & Director	1.3yrs	UK£21.00k	0.092% € 18.9k
Alistair Macdonald	Non-executive Chairman	2.3yrs	UK£100.00k	0.14% € 28.6k
John Goold	Independent Non-Executive Director	1.8yrs	UK£15.00k	1.33% € 272.9k
Parag Mallick	Member of Scientific Board	5.6yrs	no data	no data
Richard Roope	Member of Scientific Board	5.9yrs	no data	no data
Nora Pashayan	Member of Scientific Board	5.9yrs	no data	no data
Ola Winqvist	Member of Scientific Board	5.9yrs	no data	no data

5.6yrs

Average Tenure

54yo

Average Age

Experienced Board: OCY's board of directors are considered experienced (5.6 years average tenure).

Oncimmune Holdings Management

Management criteria checks 3/4

Key information

Recent management updates

Less than half of directors are independent

Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024

Oncimmune Holdings plc Announces Board Changes

Less than half of directors are independent

Oncimmune Holdings plc Announces Changes to the Board

Oncimmune Holdings plc Announces Executive Changes

Recent updates

New major risk - Shareholder dilution

No longer forecast to breakeven

New major risk - Financial data availability

Oncimmune Holdings plc Reaffirms Revenue Guidance for the Fiscal Year 2024 and Provides Earnings Guidance for the Fiscal Year 2025

New major risk - Negative shareholders equity

Oncimmune Holdings plc to Report First Half, 2024 Results on May 21, 2024

Less than half of directors are independent

Full year 2023 earnings released: UK£0.085 loss per share (vs UK£0.13 loss in FY 2022)

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024

New minor risk - Financial data availability

Oncimmune Holdings plc Announces Board Changes

Less than half of directors are independent

Oncimmune Holdings plc Announces Changes to the Board

Oncimmune Holdings plc Announces Executive Changes

Freenome Holdings, Inc. acquired Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million.

Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2023

Oncimmune Holdings plc Announces Appointment of John Goold as Non-Executive Director

Oncimmune Holdings plc has completed a Follow-on Equity Offering in the amount of £2.1 million.

Less than half of directors are independent

Full year 2022 earnings released: UK£0.14 loss per share (vs UK£0.072 loss in FY 2021)

Now 20% undervalued after recent price drop

Oncimmune Holdings plc Announces Board Changes

Less than half of directors are independent

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Oncimmune Holdings Ordinary Shares to Be Deleted from Other OTC

Oncimmune Holdings plc Announces EarlyCDT Lung Test Approved by Ministry of Health for Aragon, Spain

Full year 2021 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2020)

Oncimmune Holdings plc Announces the Pre-Publication of the First Results from Its Collaboration with Cedars-Sinai Medical Center in Los Angeles

Oncimmune Holdings plc Presents Clinical Abstracts on Melflufen At the 2021 American Society of Clinical Oncology

Oncopeptides AB (publ) Presents New Clinical and Preclinical Melflufen Data At the Upcoming European Hematology Association Meeting

First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.083 loss in 1H 2020)

New 90-day high: €2.12

Oncimmune Holdings plc to Report First Half, 2021 Results on Feb 15, 2021

Oncimmune Holdings plc Announces Steps Down of Cheung to as a Non-Executive Director, Effective 19 January 2021

New 90-day high: €2.04

Oncimmune Holdings plc Signs Commercial Contracts

New 90-day high: €1.99

Oncimmune Holdings plc, Annual General Meeting, Nov 30, 2020

Full year earnings released - €0.13 loss per share

Annual earnings released: Revenue misses expectations

Oncimmune Holdings plc to Report Fiscal Year 2020 Results on Oct 30, 2020

Oncimmune Holdings plc Initiates U.S. Expanded Access Program with Melflufen in Triple-Class Refractory Multiple Myeloma

Oncimmune Holdings plc announced that it has received £5.25 million in funding from Balderton Capital (UK) LLP and other investors

Oncimmune Holdings plc Signs Collaboration with Genentech

New 90-day high - €1.55

New 90-day high - €1.45

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age